16-28878771-G-T
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PVS1PM2PP5
The NM_004320.6(ATP2A1):c.100G>T(p.Glu34Ter) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000756 in 1,613,902 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_004320.6 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ATP2A1 | NM_004320.6 | c.100G>T | p.Glu34Ter | stop_gained | 1/23 | ENST00000395503.9 | |
ATP2A1 | NM_173201.5 | c.100G>T | p.Glu34Ter | stop_gained | 1/22 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ATP2A1 | ENST00000395503.9 | c.100G>T | p.Glu34Ter | stop_gained | 1/23 | 1 | NM_004320.6 | P4 | |
ATP2A1-AS1 | ENST00000691192.2 | n.1166C>A | non_coding_transcript_exon_variant | 1/1 | |||||
ATP2A1 | ENST00000357084.7 | c.100G>T | p.Glu34Ter | stop_gained | 1/22 | 2 | A1 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152200Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000438 AC: 11AN: 250888Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135660
GnomAD4 exome AF: 0.0000766 AC: 112AN: 1461702Hom.: 0 Cov.: 31 AF XY: 0.0000935 AC XY: 68AN XY: 727140
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152200Hom.: 0 Cov.: 32 AF XY: 0.0000807 AC XY: 6AN XY: 74350
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jun 15, 2017 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Brody myopathy Pathogenic:2Uncertain:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 28, 2023 | This sequence change creates a premature translational stop signal (p.Glu34*) in the ATP2A1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATP2A1 are known to be pathogenic (PMID: 8841193, 10914677, 23911890). This variant is present in population databases (rs141559558, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with Brody myopathy (PMID: 10914677). ClinVar contains an entry for this variant (Variation ID: 446876). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 25, 2018 | The ATP2A1 c.100G>T (p.Glu34Ter) variant is a stop-gained variant and is predicted to prematurely truncate the protein. The p.Glu34Ter variant has been reported in one study, in which it is found in a compound heterozygous state with another stop-gained variant in an individual with Brody myopathy (Odermatt et al. 2000). This variant is reported to abolish a specific restriction endonuclease site, causing cleavage of different sized fragments. Control data are unavailable for this variant, which is reported at a frequency of 0.000124 in the European (non-Finnish) population of the Exome Aggregation Consortium. Due to the potential impact of stop-gained variants and limited clinical evidence, the p.Glu34Ter variant is classified as a variant of unknown significance but suspicious for pathogenicity for Brody myopathy. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 20, 2018 | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. This variant has been previously reported in a family with Brody myopathy [PMID 10914677] - |
ATP2A1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 15, 2024 | The ATP2A1 c.100G>T variant is predicted to result in premature protein termination (p.Glu34*). This variant was reported in the compound heterozygous and homozygous state in several individuals with Brody myopathy (Odermatt et al. 2000. PubMed ID: 10914677; Molenaar et al. 2020. PubMed ID: 32040565). This variant is reported in 0.011% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Nonsense variants in ATP2A1 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at